AU3408999A - Glycine transport inhibitors - Google Patents

Glycine transport inhibitors Download PDF

Info

Publication number: AU3408999A
Authority: AU; Australia
Prior art keywords: formula; butyl; bis; fluorophenyl; piperidinyl
Prior art date: 1998-03-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU34089/99A

Other languages

English (en)

Inventor

Frans Eduard Janssens

Ludo Edmond Josephine Kennis

Walter Herman Maria Louis Luyten

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Janssen Pharmaceutica NV

Original Assignee

Janssen Pharmaceutica NV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-06

Filing date

1999-02-26

Publication date

1999-09-20

1999-02-26 Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV

1999-09-20 Publication of AU3408999A publication Critical patent/AU3408999A/en

Status Abandoned legal-status Critical Current

Links

DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 title claims description 34
239000004471 Glycine Substances 0.000 title claims description 17
239000003112 inhibitor Substances 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims description 64
-1 imidazo[1,2-a]pyridinyl Chemical group 0.000 claims description 33
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 32
150000003839 salts Chemical class 0.000 claims description 28
150000003254 radicals Chemical class 0.000 claims description 18
239000002253 acid Substances 0.000 claims description 17
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 16
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 15
239000002585 base Substances 0.000 claims description 14
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
238000000034 method Methods 0.000 claims description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
150000001204 N-oxides Chemical class 0.000 claims description 10
125000000217 alkyl group Chemical group 0.000 claims description 9
238000002360 preparation method Methods 0.000 claims description 9
125000003118 aryl group Chemical group 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 8
239000001257 hydrogen Substances 0.000 claims description 8
229910052739 hydrogen Inorganic materials 0.000 claims description 8
239000012442 inert solvent Substances 0.000 claims description 8
239000003937 drug carrier Substances 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 7
125000003545 alkoxy group Chemical group 0.000 claims description 6
210000003169 central nervous system Anatomy 0.000 claims description 6
125000002541 furyl group Chemical group 0.000 claims description 6
230000002401 inhibitory effect Effects 0.000 claims description 6
210000001428 peripheral nervous system Anatomy 0.000 claims description 6
125000001544 thienyl group Chemical group 0.000 claims description 6
206010019196 Head injury Diseases 0.000 claims description 5
208000002193 Pain Diseases 0.000 claims description 5
208000006011 Stroke Diseases 0.000 claims description 5
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 5
239000004480 active ingredient Substances 0.000 claims description 5
208000035475 disorder Diseases 0.000 claims description 5
206010015037 epilepsy Diseases 0.000 claims description 5
125000005129 aryl carbonyl group Chemical group 0.000 claims description 4
239000004202 carbamide Substances 0.000 claims description 4
239000003054 catalyst Substances 0.000 claims description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
201000006417 multiple sclerosis Diseases 0.000 claims description 4
230000004770 neurodegeneration Effects 0.000 claims description 4
208000015122 neurodegenerative disease Diseases 0.000 claims description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
CUJPFPXNDSIBPG-UHFFFAOYSA-N 1,3-propanediyl Chemical group [CH2]C[CH2] CUJPFPXNDSIBPG-UHFFFAOYSA-N 0.000 claims description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
208000028017 Psychotic disease Diseases 0.000 claims description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
239000012458 free base Substances 0.000 claims description 3
125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims description 2
239000003513 alkali Substances 0.000 claims description 2
125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
125000001769 aryl amino group Chemical group 0.000 claims description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
239000003638 chemical reducing agent Substances 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
125000001261 isocyanato group Chemical group *N=C=O 0.000 claims description 2
125000004076 pyridyl group Chemical group 0.000 claims description 2
125000001424 substituent group Chemical group 0.000 claims description 2
125000000335 thiazolyl group Chemical group 0.000 claims description 2
QIJNVLLXIIPXQT-UHFFFAOYSA-N 1-(4-fluorophenyl)propan-1-one Chemical compound CCC(=O)C1=CC=C(F)C=C1 QIJNVLLXIIPXQT-UHFFFAOYSA-N 0.000 claims 1
KYXIMIWOAAGLJI-UHFFFAOYSA-N 1-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1-(4-methylphenyl)-3-propan-2-ylurea Chemical compound C=1C=C(C)C=CC=1N(C(=O)NC(C)C)C(CC1)CCN1CCCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 KYXIMIWOAAGLJI-UHFFFAOYSA-N 0.000 claims 1
RGQMWVXEZGJXPB-UHFFFAOYSA-N 1-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-3-butyl-1-(4-methoxyphenyl)urea Chemical compound C=1C=C(OC)C=CC=1N(C(=O)NCCCC)C(CC1)CCN1CCCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 RGQMWVXEZGJXPB-UHFFFAOYSA-N 0.000 claims 1
VPDDKAHEMISYJT-UHFFFAOYSA-N 1-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-3-ethyl-1-(4-methylphenyl)urea Chemical compound C=1C=C(C)C=CC=1N(C(=O)NCC)C(CC1)CCN1CCCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VPDDKAHEMISYJT-UHFFFAOYSA-N 0.000 claims 1
SZILZUAXESPXJM-UHFFFAOYSA-N 4-[2-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]acetyl]-3-phenyl-1,3-dihydroquinoxalin-2-one Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(CC(=O)N2C3=CC=CC=C3NC(=O)C2C=2C=CC=CC=2)CC1 SZILZUAXESPXJM-UHFFFAOYSA-N 0.000 claims 1
YCIPQJTZJGUXND-UHFFFAOYSA-N Aglaia odorata Alkaloid Natural products C1=CC(OC)=CC=C1C1(C(C=2C(=O)N3CCCC3=NC=22)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 YCIPQJTZJGUXND-UHFFFAOYSA-N 0.000 claims 1
125000001475 halogen functional group Chemical group 0.000 claims 1
150000002431 hydrogen Chemical class 0.000 claims 1
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
SQGPXLQVUBFEAE-UHFFFAOYSA-N n-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1-(imidazo[1,2-a]pyridin-2-ylmethyl)benzimidazol-2-amine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2N=C3C=CC=CN3C=2)CC1 SQGPXLQVUBFEAE-UHFFFAOYSA-N 0.000 claims 1
125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 1
VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 claims 1
230000002829 reductive effect Effects 0.000 claims 1
239000000203 mixture Substances 0.000 description 27
239000000243 solution Substances 0.000 description 14
239000000543 intermediate Substances 0.000 description 13
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
MUBZPKHOEPUJKR-UHFFFAOYSA-L Oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 8
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
210000004027 cell Anatomy 0.000 description 8
239000003826 tablet Substances 0.000 description 8
102000011714 Glycine Receptors Human genes 0.000 description 7
108010076533 Glycine Receptors Proteins 0.000 description 7
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 7
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 7
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
101710083171 Sodium- and chloride-dependent glycine transporter 1 Proteins 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
201000010099 disease Diseases 0.000 description 6
239000002858 neurotransmitter agent Substances 0.000 description 6
102100023145 Sodium- and chloride-dependent glycine transporter 1 Human genes 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
230000000694 effects Effects 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
108010078791 Carrier Proteins Proteins 0.000 description 4
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
101710083167 Sodium- and chloride-dependent glycine transporter 2 Proteins 0.000 description 4
102100028886 Sodium- and chloride-dependent glycine transporter 2 Human genes 0.000 description 4
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
230000006870 function Effects 0.000 description 4
238000004811 liquid chromatography Methods 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
210000002569 neuron Anatomy 0.000 description 4
239000003921 oil Substances 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
229910000029 sodium carbonate Inorganic materials 0.000 description 4
210000000278 spinal cord Anatomy 0.000 description 4
239000000725 suspension Substances 0.000 description 4
210000000225 synapse Anatomy 0.000 description 4
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
208000024827 Alzheimer disease Diseases 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
102000010726 Glycine Plasma Membrane Transport Proteins Human genes 0.000 description 3
108010063380 Glycine Plasma Membrane Transport Proteins Proteins 0.000 description 3
UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 3
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 3
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
239000000654 additive Substances 0.000 description 3
230000005540 biological transmission Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
230000002964 excitative effect Effects 0.000 description 3
239000008103 glucose Substances 0.000 description 3
125000005843 halogen group Chemical group 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
230000000946 synaptic effect Effects 0.000 description 3
230000005062 synaptic transmission Effects 0.000 description 3
GKRPRMLFFJTPKC-UHFFFAOYSA-N 4-chloro-1-thiophen-2-ylbutan-2-one Chemical compound ClCCC(=O)CC1=CC=CS1 GKRPRMLFFJTPKC-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
208000008238 Muscle Spasticity Diseases 0.000 description 2
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
210000000133 brain stem Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000013078 crystal Substances 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
229940050410 gluconate Drugs 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
210000000653 nervous system Anatomy 0.000 description 2
230000016273 neuron death Effects 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
150000007530 organic bases Chemical class 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
150000002978 peroxides Chemical class 0.000 description 2
XCRBXWCUXJNEFX-UHFFFAOYSA-N peroxybenzoic acid Chemical group OOC(=O)C1=CC=CC=C1 XCRBXWCUXJNEFX-UHFFFAOYSA-N 0.000 description 2
239000006187 pill Substances 0.000 description 2
125000003386 piperidinyl group Chemical group 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
XXQBEVHPUKOQEO-UHFFFAOYSA-N potassium superoxide Chemical compound [K+].[K+].[O-][O-] XXQBEVHPUKOQEO-UHFFFAOYSA-N 0.000 description 2
239000000047 product Substances 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
238000010956 selective crystallization Methods 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000012453 solvate Substances 0.000 description 2
208000018198 spasticity Diseases 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
229930192474 thiophene Natural products 0.000 description 2
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
OMIVCRYZSXDGAB-UHFFFAOYSA-N 1,4-butanediyl Chemical group [CH2]CC[CH2] OMIVCRYZSXDGAB-UHFFFAOYSA-N 0.000 description 1
UXXLTPGCINZEFM-UHFFFAOYSA-N 1-[4-chloro-1-(4-fluorophenyl)butyl]-4-fluorobenzene Chemical compound C1=CC(F)=CC=C1C(CCCCl)C1=CC=C(F)C=C1 UXXLTPGCINZEFM-UHFFFAOYSA-N 0.000 description 1
UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
MKHGVMIXRPGHOO-UHFFFAOYSA-N 2-(benzenesulfonyl)-3-phenyloxaziridine Chemical compound C=1C=CC=CC=1S(=O)(=O)N1OC1C1=CC=CC=C1 MKHGVMIXRPGHOO-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
GSLTVFIVJMCNBH-UHFFFAOYSA-N 2-isocyanatopropane Chemical compound CC(C)N=C=O GSLTVFIVJMCNBH-UHFFFAOYSA-N 0.000 description 1
125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
125000005916 2-methylpentyl group Chemical group 0.000 description 1
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
KSTFHYBYFDYWSD-UHFFFAOYSA-N 3-piperidin-4-yl-1,4-dihydroquinazolin-2-one Chemical compound O=C1NC2=CC=CC=C2CN1C1CCNCC1 KSTFHYBYFDYWSD-UHFFFAOYSA-N 0.000 description 1
UWDQCUJVTIQUDQ-UHFFFAOYSA-N 4,4-bis(4-fluorophenyl)butanal Chemical compound C1=CC(F)=CC=C1C(CCC=O)C1=CC=C(F)C=C1 UWDQCUJVTIQUDQ-UHFFFAOYSA-N 0.000 description 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
241000209763 Avena sativa Species 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
208000014094 Dystonic disease Diseases 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
102000018899 Glutamate Receptors Human genes 0.000 description 1
108010027915 Glutamate Receptors Proteins 0.000 description 1
101000684936 Homo sapiens Sodium- and chloride-dependent glycine transporter 1 Proteins 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
206010061285 Mental disorder due to a general medical condition Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
208000016285 Movement disease Diseases 0.000 description 1
208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
208000002033 Myoclonus Diseases 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
102000005665 Neurotransmitter Transport Proteins Human genes 0.000 description 1
108010084810 Neurotransmitter Transport Proteins Proteins 0.000 description 1
HJGXPWMLXWHBQF-UHFFFAOYSA-N OC(=O)C(O)=O.CCOCCn1c(CN2CCN(CCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)nc2cccnc12 Chemical compound OC(=O)C(O)=O.CCOCCn1c(CN2CCN(CCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)nc2cccnc12 HJGXPWMLXWHBQF-UHFFFAOYSA-N 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical class OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
241001279009 Strychnos toxifera Species 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
201000004810 Vascular dementia Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
150000003797 alkaloid derivatives Chemical class 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
239000003282 amino acid receptor affecting agent Substances 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
229940125682 antidementia agent Drugs 0.000 description 1
239000000164 antipsychotic agent Substances 0.000 description 1
229940005529 antipsychotics Drugs 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
229960001701 chloroform Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000019771 cognition Effects 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
229940125797 compound 12 Drugs 0.000 description 1
229940126543 compound 14 Drugs 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
229940126214 compound 3 Drugs 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
239000003179 convulsant agent Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000000498 cooling water Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000004821 distillation Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
208000010118 dystonia Diseases 0.000 description 1
239000003480 eluent Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
239000012909 foetal bovine serum Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
229940052308 general anesthetics halogenated hydrocarbons Drugs 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
230000000848 glutamatergic effect Effects 0.000 description 1
150000002306 glutamic acid derivatives Chemical class 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
150000002333 glycines Chemical class 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
102000058125 human SLC6A9 Human genes 0.000 description 1
XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical class C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
XDYHDLLKHFVVSE-UHFFFAOYSA-N hydrate;dihydrobromide Chemical compound O.Br.Br XDYHDLLKHFVVSE-UHFFFAOYSA-N 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
229910000041 hydrogen chloride Inorganic materials 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
CVVIJWRCGSYCMB-UHFFFAOYSA-N hydron;piperazine;dichloride Chemical compound Cl.Cl.C1CNCCN1 CVVIJWRCGSYCMB-UHFFFAOYSA-N 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
208000013403 hyperactivity Diseases 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
150000004668 long chain fatty acids Chemical class 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
FYYHWMGAXLPEAU-OUBTZVSYSA-N magnesium-25 atom Chemical compound [25Mg] FYYHWMGAXLPEAU-OUBTZVSYSA-N 0.000 description 1
239000002609 medium Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
150000004972 metal peroxides Chemical class 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000004118 muscle contraction Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
230000003040 nociceptive effect Effects 0.000 description 1
239000002664 nootropic agent Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-M octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
150000001451 organic peroxides Chemical class 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000003961 penetration enhancing agent Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
235000019371 penicillin G benzathine Nutrition 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
150000004965 peroxy acids Chemical group 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000000053 physical method Methods 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
210000000063 presynaptic terminal Anatomy 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000004129 prosencephalon Anatomy 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
238000005932 reductive alkylation reaction Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
PFUVRDFDKPNGAV-UHFFFAOYSA-N sodium peroxide Chemical compound [Na+].[Na+].[O-][O-] PFUVRDFDKPNGAV-UHFFFAOYSA-N 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
208000020431 spinal cord injury Diseases 0.000 description 1
239000004544 spot-on Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
229960005453 strychnine Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000027682 synaptic transmission, glycinergic Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 1
239000012085 test solution Substances 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000009466 transformation Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
238000001665 trituration Methods 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AU34089/99A 1998-03-06 1999-02-26 Glycine transport inhibitors Abandoned AU3408999A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP98200701		1998-03-06
EP98200701		1998-03-06
PCT/EP1999/001309 WO1999044596A2 (fr)	1998-03-06	1999-02-26	Inhibiteurs du transport de la glycine

Publications (1)

Publication Number	Publication Date
AU3408999A true AU3408999A (en)	1999-09-20

Family

ID=8233444

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU34089/99A Abandoned AU3408999A (en)	1998-03-06	1999-02-26	Glycine transport inhibitors

Country Status (17)

Country	Link
EP (1)	EP1059922A2 (fr)
JP (1)	JP2002505277A (fr)
KR (1)	KR20010032968A (fr)
CN (1)	CN1292698A (fr)
AU (1)	AU3408999A (fr)
BG (1)	BG104685A (fr)
BR (1)	BR9907951A (fr)
CA (1)	CA2322164A1 (fr)
EE (1)	EE200000482A (fr)
HR (1)	HRP20000523A2 (fr)
HU (1)	HUP0101048A2 (fr)
IL (1)	IL138228A0 (fr)
NO (1)	NO20004431L (fr)
PL (1)	PL343435A1 (fr)
SK (1)	SK13082000A3 (fr)
TR (1)	TR200002567T2 (fr)
WO (1)	WO1999044596A2 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE259796T1 (de)	1999-06-28	2004-03-15	Janssen Pharmaceutica Nv	Respiratorisches syncytialvirus replikation inhibitoren
UA73749C2 (en) *	1999-11-01	2005-09-15		Diarylenines
AU2001254546A1 (en) *	2000-04-20	2001-11-07	Nps Allelix Corp.	Aminopiperidines
DE10040016A1 (de) *	2000-08-16	2002-02-28	Boehringer Ingelheim Pharma	Neue beta-Amyloid Inhibitoren, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US20020120149A1 (en)	2000-09-08	2002-08-29	Ali Syed M.	Substituted hydrazine derivatives
AU2001290786A1 (en)	2000-09-14	2002-03-26	Gliatech, Inc.	Nitrogen-containing compounds and their use as glycine transport inhibitors
AR032653A1 (es)	2001-02-09	2003-11-19	Telik Inc	Inhibidores heterociclicos del trasportador de glicina 2 composiciones farmaceuticas, uso y metodos.
US7030150B2 (en)	2001-05-11	2006-04-18	Trimeris, Inc.	Benzimidazole compounds and antiviral uses thereof
BRPI0414209B8 (pt)	2003-09-09	2021-05-25	Hoffmann La Roche	derivados de 1-(2-amino-benzol)-piperazina, seus processos de preparação e seu uso, e medicamento
AU2004269892B2 (en) *	2003-09-09	2010-03-11	F. Hoffmann-La Roche Ag	1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
WO2005058885A2 (fr) *	2003-12-18	2005-06-30	Glaxo Group Limited	Composes
TW200630337A (en)	2004-10-14	2006-09-01	Euro Celtique Sa	Piperidinyl compounds and the use thereof
SI1828154T1 (sl) *	2004-12-09	2009-08-31	Hoffmann La Roche	Derivati fenil-piperazin metanona
MX2007006896A (es) *	2004-12-15	2007-06-26	Hoffmann La Roche	Fenil-metanonas bi- y triciclicas sustituidas como inhibidores del transportador 1 de glicina (glyt-1) para el tratamiento de la enfermedad de alzheimer.
GB0428233D0 (en) *	2004-12-23	2005-01-26	Glaxo Group Ltd	Compounds
PE20061156A1 (es)	2004-12-23	2006-12-16	Glaxo Group Ltd	Derivados de benzamida como agentes inhibidores del transportador de glicina
US7485637B2 (en)	2005-01-04	2009-02-03	Hoffmann-La Roche Inc.	Benzoyl-tetrahydropiperidine derivatives
CN101356163A (zh) *	2005-01-06	2009-01-28	弗·哈夫曼-拉罗切有限公司	作为甘氨酸转运体1(GlyT-1)抑制剂用于治疗神经学和神经精神病学障碍的硫烷基取代的苯甲酮化合物
DE602005022113D1 (de) *	2005-01-07	2010-08-12	Hoffmann La Roche	Phenyl)methanon-derivate als glycin-transporter 1 (glyt-1) hemmer zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
ATE435650T1 (de) *	2005-01-18	2009-07-15	Hoffmann La Roche	2,5-disubstituierte phenylmethanonderivative als glycintransporter-1-inhibitoren (glyt-1) zur behandlung von neurologischen und neuropsychiatrischen störungen
KR100915472B1 (ko)	2005-01-26	2009-09-03	에프. 호프만-라 로슈 아게	페닐 메탄온 유도체 및 그의 글라이신 트랜스포터 1억제제로서의 용도
ES2334578T3 (es) *	2005-02-07	2010-03-12	F. Hoffmann-La Roche Ag	Fenil-metanonas sustituidas por heterociclo como inhibidores del transportador 1 de la glicina.
CN100341871C (zh) *	2005-06-03	2007-10-10	复旦大学	含哌啶结构的有机硫化合物，制备方法和应用
WO2007110449A1 (fr)	2006-03-29	2007-10-04	Euro-Celtique S.A.	Composés de benzènesulfonamide et utilisation de ceux-ci
TW200812963A (en)	2006-04-13	2008-03-16	Euro Celtique Sa	Benzenesulfonamide compounds and the use thereof
WO2007118853A1 (fr)	2006-04-13	2007-10-25	Euro-Celtique S.A.	Benzènesulfonamides et leur emploi en tant qu'agents bloquants des canaux calcium
EA017471B1 (ru) *	2006-11-01	2012-12-28	Пэдью Фарма Л.П.	Фенилпропионамидные соединения и их применение
FR2910320B1 (fr) *	2006-12-21	2009-02-13	Galderma Res & Dev S N C Snc	Emulsion comprenant au moins un retinoide et du peroxyde de benzole
FR2910321B1 (fr)	2006-12-21	2009-07-10	Galderma Res & Dev S N C Snc	Gel creme comprenant au moins un retinoide et du peroxyde de benzole
WO2008124118A1 (fr)	2007-04-09	2008-10-16	Purdue Pharma L.P.	Composés benzènesulfonylés et leur utilisation
WO2009040659A2 (fr)	2007-09-28	2009-04-02	Purdue Pharma L.P.	Composés benzènesulfonamides et leurs utilisations
ES2486299T3 (es) *	2007-12-12	2014-08-18	Amgen Inc.	Inhibidores del transportador de glicina 1

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4219559A (en) *	1979-01-10	1980-08-26	Janssen Pharmaceutica N.V.	N-Heterocyclyl-4-piperidinamines
CA1140119A (fr) *	1978-04-03	1983-01-25	Joseph Torremans	Nouvelles n-heterocycle-4-piperidinamines
PH23995A (en) *	1984-01-09	1990-02-09	Janssen Pharmaceutica Nv	4((bicycle heterocyclyl)-methyl and hetero)piperidines
US4695575A (en) *	1984-11-13	1987-09-22	Janssen Pharmaceutica, N.V.	4-[(bicycle heterocyclyl)-methyl and -hetero]-piperidines
WO1999025353A1 (fr) *	1997-11-13	1999-05-27	Merck Sharp & Dohme Limited	Utilisations therapeutiques de derives de triazolopyridazine

1999
- 1999-02-26 HR HR20000523A patent/HRP20000523A2/hr not_active Application Discontinuation
- 1999-02-26 AU AU34089/99A patent/AU3408999A/en not_active Abandoned
- 1999-02-26 TR TR2000/02567T patent/TR200002567T2/xx unknown
- 1999-02-26 IL IL13822899A patent/IL138228A0/xx unknown
- 1999-02-26 SK SK1308-2000A patent/SK13082000A3/sk unknown
- 1999-02-26 CA CA002322164A patent/CA2322164A1/fr not_active Abandoned
- 1999-02-26 JP JP2000534198A patent/JP2002505277A/ja not_active Withdrawn
- 1999-02-26 KR KR1020007006315A patent/KR20010032968A/ko not_active Withdrawn
- 1999-02-26 WO PCT/EP1999/001309 patent/WO1999044596A2/fr not_active Ceased
- 1999-02-26 HU HU0101048A patent/HUP0101048A2/hu unknown
- 1999-02-26 EP EP99915541A patent/EP1059922A2/fr not_active Withdrawn
- 1999-02-26 CN CN998036471A patent/CN1292698A/zh active Pending
- 1999-02-26 BR BR9907951-8A patent/BR9907951A/pt not_active Application Discontinuation
- 1999-02-26 EE EEP200000482A patent/EE200000482A/xx unknown
- 1999-02-26 PL PL99343435A patent/PL343435A1/xx not_active Application Discontinuation
2000
- 2000-08-11 BG BG104685A patent/BG104685A/xx unknown
- 2000-09-05 NO NO20004431A patent/NO20004431L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
KR20010032968A (ko)	2001-04-25
IL138228A0 (en)	2001-10-31
HRP20000523A2 (en)	2001-02-28
BG104685A (en)	2001-04-30
PL343435A1 (en)	2001-08-13
NO20004431L (no)	2000-10-30
SK13082000A3 (sk)	2001-03-12
CA2322164A1 (fr)	1999-09-10
NO20004431D0 (no)	2000-09-05
WO1999044596A2 (fr)	1999-09-10
EP1059922A2 (fr)	2000-12-20
TR200002567T2 (tr)	2000-11-21
CN1292698A (zh)	2001-04-25
EE200000482A (et)	2002-02-15
BR9907951A (pt)	2001-01-30
HUP0101048A2 (hu)	2001-10-28
WO1999044596A3 (fr)	2000-02-17
JP2002505277A (ja)	2002-02-19

Publication	Publication Date	Title
AU3408999A (en)	1999-09-20	Glycine transport inhibitors
AU2016299484B2 (en)	2019-08-01	1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
US6521621B1 (en)	2003-02-18	1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives
CA2322136A1 (fr)	1999-09-10	Inhibiteurs du transport de la glycine
EP0855999B1 (fr)	2001-10-04	Derives 1-(piperidinyl 1,2-disubstitue)-4-substitue-piperidine comme antagonistes des recepteurs de la tachykinine
US5731309A (en)	1998-03-24	Substituted heteroalkyleneamine neurokinin antagonists
US5371094A (en)	1994-12-06	Azaheterocyclylmethyl-chromans for treating axiety
PL207384B1 (pl)	2010-12-31	Pochodne benzotiazolu, sposób ich wytwarzania, lek i ich zastosowanie do wytwarzania leku
KR20060095865A (ko)	2006-09-04	글리신 수송 억제제로서의 비시클릭 [3.1.0] 유도체
JP2008138007A (ja)	2008-06-19	タキキニン受容体アンタゴニストとしての５−（４−置換−ピペリジニル−１）−３−アリール−ペンタン酸誘導体
JP2012530129A (ja)	2012-11-29	Ｋａｔｉｉ阻害剤としての二環式および三環式化合物
US4990521A (en)	1991-02-05	4-(aroylamino)piperidine-butanimide derivatives
AU747815B2 (en)	2002-05-23	Cyclic amide compounds
WO2017042643A1 (fr)	2017-03-16	Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1
EP4289425A2 (fr)	2023-12-13	Nouveaux dérivés de benzimidazole substitués utilisés en tant qu'inhibiteurs de la d-amino-acide oxydase (daao)
MXPA00008690A (en)	2001-07-09	Glycine transport inhibitors
CZ20003146A3 (cs)	2000-12-13	Inhibitory přenosu glycinu
EP3713940B1 (fr)	2022-05-04	Azacycles substitués utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1
HK40097730A (en)	2024-03-22	Novel substituted benzimidazole derivatives as d-amino acid oxidase (daao) inhibitors
CZ20012711A3 (cs)	2002-05-15	Deriváty kyseliny hydroxamové obsahující alkynylovou skupinu, jejich příprava a jejich pouľití jako inhibitorů metaloproteináz mezibuněčné hmoty (MMP) a inhibitorů enzymu konvertujícího TNF-alfa (TACE)
MXPA00008692A (en)	2001-07-09	Glycine transport inhibitors
CZ20003147A3 (cs)	2000-11-15	Inhibitory přenosu glycinu
WO2010087761A1 (fr)	2010-08-05	Composés 2-aza-bicyclo[2.2.2]octane et leurs utilisations
HK1011205B (en)	2002-03-08	1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives as tachykinin receptor antagonists

Legal Events

Date	Code	Title	Description
2004-09-30	MK4	Application lapsed section 142(2)(d) - no continuation fee paid for the application